Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Hematologic Complications of Immune Checkpoint Inhibitors.

Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB.

Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.

2.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

3.

Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.

Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM.

Cancer Immunol Res. 2019 Jan;7(1):86-99. doi: 10.1158/2326-6066.CIR-17-0692. Epub 2018 Nov 9.

PMID:
30413431
4.

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC.

Leuk Res. 2018 Feb;65:67-73. doi: 10.1016/j.leukres.2017.12.012. Epub 2018 Jan 2.

5.

Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics.

Earl DC, Ferrell PB Jr, Leelatian N, Froese JT, Reisman BJ, Irish JM, Bachmann BO.

Nat Commun. 2018 Jan 2;9(1):39. doi: 10.1038/s41467-017-02470-8.

6.

Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.

Roussel M, Ferrell PB Jr, Greenplate AR, Lhomme F, Le Gallou S, Diggins KE, Johnson DB, Irish JM.

J Leukoc Biol. 2017 Aug;102(2):437-447. doi: 10.1189/jlb.5MA1116-457R. Epub 2017 Apr 11.

7.

Systems immune monitoring in cancer therapy.

Greenplate AR, Johnson DB, Ferrell PB Jr, Irish JM.

Eur J Cancer. 2016 Jul;61:77-84. doi: 10.1016/j.ejca.2016.03.085. Epub 2016 May 4. Review.

8.

High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.

Ferrell PB Jr, Diggins KE, Polikowsky HG, Mohan SR, Seegmiller AC, Irish JM.

PLoS One. 2016 Apr 13;11(4):e0153207. doi: 10.1371/journal.pone.0153207. eCollection 2016.

9.

Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.

Greenplate AR, Johnson DB, Roussel M, Savona MR, Sosman JA, Puzanov I, Ferrell PB, Irish JM.

Cancer Immunol Res. 2016 Jun;4(6):474-480. doi: 10.1158/2326-6066.CIR-15-0213. Epub 2016 Mar 10.

10.

Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data.

Diggins KE, Ferrell PB Jr, Irish JM.

Methods. 2015 Jul 1;82:55-63. doi: 10.1016/j.ymeth.2015.05.008. Epub 2015 May 13.

11.

Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

Ferrell PB Jr, McLeod HL.

Pharmacogenomics. 2008 Oct;9(10):1543-6. doi: 10.2217/14622416.9.10.1543.

12.

Frequency of transforming Epstein-Barr virus in oropharyngeal secretions of rheumatoid arthritis patients.

Aitcheson CT, Wilson GL, Ferrell PB, Tan EM.

Intervirology. 1983;19(3):135-43.

PMID:
6299994
13.

Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis.

Ferrell PB, Aitcheson CT, Pearson GR, Tan EM.

J Clin Invest. 1981 Mar;67(3):681-7.

14.

Epstein-Barr (EB) virus antibodies in rheumatoid arthritis.

Ferrell PB, Tan EM.

Springer Semin Immunopathol. 1981;4(2):181-91. No abstract available.

PMID:
6275562

Supplemental Content

Loading ...
Support Center